BRVEBraveheart Bio Inc. Common Stock
27.58USD-4.80%Mkt Cap: 1.95B $P/E: —3d ago
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-18…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap1.95B $
Enterprise Value905.87M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-80.23M $
Revenue/Share—
Last Price27.58 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees30
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-10.67
EPS (TTM)-1.73
EPS (Forward)—
52W Range
24.6140% of range32.00
52W High32.00 USD
52W Low24.61 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.20M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-79.91M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.93
Current Ratio8.11
Quick Ratio8.06
Book Value/Sh-2.5710 USD
Cash/Share2.643 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.70.65M
Float304.24K
Insiders68.59%
Institutions15.95%
Technical
SMA 5027.48 (+0.4%)
SMA 20027.48 (+0.4%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)749.63K
Avg Vol (10d)447.18K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—